India Pharma Outlook Team | Friday, 01 April 2022
Drug maker Lupin on Thursday told, its New Jersey facility has received 13 observations from the US drug regulator. The facility accounts for less than 5 percent Lupin’s global turnover. The observations do not, however, imply any restriction on supplies.
US FDA inspection of the Company’s Somerset, New Jersey facility. The USFDA has concluded an inspection at the Company’s wholly owned subsidiary Novel Laboratories, Inc., based in Somerset, NJ.
The inspection commenced on March 7, 2020 and concluded on March 30, 2022.The inspection closed with thirteen observations.,” Lupin said in a statement. The firm added that It is confident of addressing these issues with the regulator “We are confident of addressing these observations and will work closely with the Agency to address their concerns.
We uphold quality and compliance with utmost importance and are committed to be compliant with Good Manufacturing Practice standards across all our facilities,” the drugmaker said. Lupin said that this would not have any impact on the supplies or existing revenues from operations of this facility.
, CDSCO.jpg)
